A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats

Cancer Letters

Volumn 233, Issue 1, 2006, Pages 108-116

  Tsuzuki, Makiko ^a   Wu, Wenwen ^a   Nishikawa, Hiroyuki ^a   Hayami, Ryosuke ^a   Oyake, Daisuke ^a   Yabuki, Yukari ^a   Fukuda, Mamoru ^a   Ohta, Tomohiko ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BARD1; BRCA1; RING finger; Splicing variant; Ubiquitin

Indexed keywords

ANKYRIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; COMPLEMENTARY DNA; MESSENGER RNA; RNA;

ALTERNATIVE RNA SPLICING; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN; CONTROLLED STUDY; DNA LIBRARY; EXON; GENE DELETION; GENETIC VARIABILITY; HELA CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT;

AMINO ACID SEQUENCE; ANKYRIN REPEAT; BRCA1 PROTEIN; CELL LINE, TUMOR; CLEAVAGE STIMULATION FACTOR; CYTOPLASM; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 32244435753     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.03.012     Document Type: Article

References (23)

1. A.R. Venkitaraman Cancer susceptibility and the functions of BRCA1 and BRCA2 Cell 108 2002 171 182
2. R. Hashizume, M. Fukuda, I. Maeda, H. Nishikawa, D. Oyake, and Y. Yabuki The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation J. Biol. Chem. 276 2001 14537 14540
3. A. Hershko, and A. Ciechanover The ubiquitin system Annu. Rev. Biochem. 67 1998 425 479
4. H. Nishikawa, S. Ooka, K. Sato, K. Arima, J. Okamoto, and R.E. Klevit Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase J. Biol. Chem. 279 2004 3916 3924
5. F. Wu-Baer, K. Lagrazon, W. Yuan, and R. Baer The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin J. Biol. Chem. 278 2003 34743 34746
6. K. Sato, R. Hayami, W. Wu, T. Nishikawa, H. Nishikawa, and Y. Okuda Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase J. Biol. Chem. 279 2004 30919 30922
7. H. Ruffner, C.A. Joazeiro, D. Hemmati, T. Hunter, and I.M. Verma Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity Proc. Natl Acad. Sci. USA 98 2001 5134 5139
8. P.S. Brzovic, J.R. Keeffe, H. Nishikawa, K. Miyamoto, D. Fox 3rd, and M. Fukuda Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex Proc. Natl Acad. Sci. USA 100 2003 5646 5651
9. V. Joukov, J. Chen, E.A. Fox, J.B. Green, and D.M. Livingston Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development Proc. Natl Acad. Sci. USA 98 2001 12078 12083
10. E.E. McCarthy, J.T. Celebi, R. Baer, and T. Ludwig Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability Mol. Cell. Biol. 23 2003 5056 5063
11. C. Ghimenti, E. Sensi, S. Presciuttini, I.M. Brunetti, P. Conte, G. Bevilacqua, and M.A. Caligo Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations Genes Chromosomes Cancer 33 2002 235 242
12. Y. Miki, J. Swensen, D. Shattuck-Eidens, P.A. Futreal, K. Harshman, and S. Tavtigian A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 1994 66 71
13. S. Thakur, H.B. Zhang, Y. Peng, H. Le, B. Carroll, and T. Ward Localization of BRCA1 and a splice variant identifies the nuclear localization signal Mol. Cell. Biol. 17 1997 444 452
14. C.A. Wilson, M.N. Payton, G.S. Elliott, F.W. Buass, E.E. Cajulis, and D. Grosshans Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b Oncogene 14 1997 1 16
15. X. Xu, K.U. Wagner, D. Larson, Z. Weaver, C. Li, and T. Ried Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation Nat. Genet. 22 1999 37 43
16. L.C. Wu, Z.W. Wang, J.T. Tsan, M.A. Spillman, A. Phung, and X.L. Xu Identification of a RING protein that can interact in vivo with the BRCA1 gene product Nat. Genet. 14 1996 430 440
17. M. Fabbro, J.A. Rodriguez, R. Baer, and B.R. Henderson BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export J. Biol. Chem. 277 2002 21315 21324
18. J.A. Rodriguez, S. Schuchner, W.W. Au, M. Fabbro, and B.R. Henderson Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1 Oncogene 23 2004 1809 1820
19. F.E. Kleiman, and J.L. Manley Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50 Science 285 1999 1576 1579
20. Y. Takagaki, J.L. Manley, C.C. MacDonald, J. Wilusz, and T. Shenk A multisubunit factor, CstF, is required for polyadenylation of mammalian pre-mRNAs Genes Dev. 4 1990 2112 2120
21. F.E. Kleiman, and J.L. Manley The BARD1-CstF-50 interaction links mRNA 3′ end formation to DNA damage and tumor suppression Cell 104 2001 743 753
22. C.E. Jefford, A. Feki, J. Harb, K.H. Krause, and I. Irminger-Finger Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic activity Oncogene 23 2004 3509 3520
23. X. Yu, C.C. Chini, M. He, G. Mer, and J. Chen The BRCT domain is a phospho-protein binding domain Science 302 2003 639 642